News

Todos Medical CEO Provides Letter to Shareholders

New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – January 5, 2022 – Todos

Medical, Ltd. (OTCQB: TOMDF), a

comprehensive medical diagnostics and related solutions company, announced that

its President & CEO Gerald Commissiong today issued a letter to shareholders

outlining the Company progresses towards a national exchange listing expected

in the first half of 2022.

Dear Valued Shareholder,

I would like to thank you

for joining us in our journey here at Todos to transform the course of the

COVID-19 pandemic and help patients with cancer and Alzheimer’s get better

access to diagnostic tools that could dramatically impact their health. I’m

going to touch on the key themes of great interest to our shareholders and hopefully

set out the key plans we have that we believe will drive shareholder value in

the months ahead.

Acquisition of NLC Pharma

Assets and Formation of 3CL Sciences

We continue to make good

progress to complete the acquisition of NLC Pharma’s assets, and have updated

the timeline expected to close the transaction to this month January 2022. As a

reminder, Todos and NLC Pharma are currently operating under our active joint

venture with NLC Pharma called COVID Antigen Test Killer (CATK) established in

Q2/2020 where Todos has been funding the development and commercialization of

3CL protease biology-related products that include Tollovid®, Tollovid Daily,

Tollovir and TolloTest. As a reminder, Dr. Dorit Arad of NLC Pharma is a

pioneer in the field of 3CL protease biology whose lab was the first to purify

the 3C and 3CL proteases in the early 2000s and is slated to become the Chief

Scientific Officer of 3CL Sciences.

Tollovid and Tollovid Daily

are dietary supplements products that have received Certificates of Free Sale

(CFS) from the US Food & Drug Administration (FDA) with 2 allowed claims:

1)     Support

and maintain healthy immune function

2)     3CL

protease inhibitor (based on in vitro data)

These are important products

available for purchase now on Amazon, Alibaba and our own website www.MyTollovid.com that empower people to make decisions

now to support their immune system. We have seen record sales of Tollovid in

the last month as increasing awareness of the significant benefit of 3CL

protease inhibitors has gained international attention, and we believe we are

uniquely positioned to meet that demand given that we have 3CL protease

inhibitor products with authorized FDA claims on the market now in the United

States and a partner in Europe via T Cell Protect Hellas that is preparing to

distribute Tollovid Daily throughout Europe.

In parallel, we are developing

botanical drug candidate Tollovir for the treatment of COVID-19 in hospitalized

patients. Tollovir is a combination of herbal ingredients that have two

specific compounds (NLC-EXT-1 and NLC-EXT-2) discovered by Dr. Arad through

research under the joint venture that have 1) potent 3CL protease inhibition

via sub nanomolar binding affinity activity and 2) anti-cytokine activity. We

believe the dual mechanisms of Tollovir are critical in the hospitalized

setting because they are synergistic in reducing the hyper-inflammation that

likely drove the patient to the hospital and stopping the replication of the

virus that likely created the hyper-inflammation in the first place.

The

virus can maintain its activity at low levels for at least 3 months and

research has shown it can persist for up to 8 months 1. Efforts

aimed at reducing the hyper-inflammation and stopping the replication of the

virus that created the inflammation feedback loop should be able to quell the

cycle that causes hospitalized symptoms and death. It is very important to

stabilize patients in order to get them out of the hospital faster so we can

reduce the COVID burden on hospital systems. This time to stabilization is

actually our primary endpoint in the current study. We believe we can produce

in the tens of millions of treatment courses of Tollovir in 2022 to meet the

demand for drug-grade 3CL protease inhibitors. We will be working with our

European partners T-Cell Protect Hellas S. A. to gain Emergency Use

Authorization (EUA) in Greece, and of course 3CL Sciences itself, as an

Israel-based company, will be looking to advance EUA in Israel. We also expect

we could receive EUA in other jurisdictions depending on the need in those

jurisdictions. Given that we do not know which variant may emerge next, the

variant-independent nature of the 3CL protease inhibitor products we are

bringing forward will be a critical part of the fight against COVID-19 going

forward.

We continue to believe that

3CL protease diagnostics could represent a sea-change in the COVID diagnostics

market and TolloTest is uniquely positioned to meet that demand. On average,

lateral flow antigen tests show evidence of disease 9 days after infection well

after symptoms appear, but we expect our TolloTest to significantly cut that

time and show evidence as early as 1 to 3 days before symptoms appear. The 3CL

protease develops in the body 70 times faster than a virion, making detection

easier.  We have developed prototype models for mass screening systems for

point-of-entry access to airports, schools, offices, sports arenas and other

areas where large groups of people will interact indoors and will be building

the prototype in the first half of 2022, and intend to partner the single use

point of care intellectual property to a group currently in the market looking

to differentiate their current nucleocapsid antigen testing kits by having an

additional unique marker that could identify the virus earlier than currently

available antigen tests.

COVID Testing

We have seen record demand

for PCR testing at our CLIA/CAP lab Provista Diagnostics in recent weeks, and

we are ramping up hiring to meet the substantial demand we expect will continue

in the months ahead for COVID testing. With this demand increasing, we are

seeing increasing sample flow from our reference lab clients and have received

a number of new contracts to support new testing sites that are being

established throughout the New York City area and the Atlanta area.

COVID testing at our client

labs through our Corona Diagnostics subsidiary are also seeing increasing

demand and we are looking at ways to more closely align with our labs to our

mutual benefit so we can help them further scale to meet the demands of their

local communities.

Proprietary testing:

Videssa breast cancer test and LymPro Alzheimer’s test

Todos was founded to bring

proprietary tests for immune-related disorder to market beginning with breast

cancer. To that end, our Videssa breast cancer test is the priority product

candidate to bring into the market because it will differentiate our CLIA lab

and allow us to provide a comprehensive suite of testing that will be

‘stickier’ with ordering physicians.  Women with dense breasts or those

who are at high risk of cancer, will view our CLIA lab as a next generation

cancer testing lab that can screen for both breast cancer and COVID. Building

on this concept will allow us to tie together COVID testing, including monitoring

for Long COVID biology that we intend to bring online later this year, with

testing for Cancer which will also need to be monitored closely, especially

cancer patients who are post-COVID. To this end, we intend to launch a clinical

study in 2022 to meet the criteria to bring this important test into the market

and gain initial reimbursement that will allow us to drive sales in 2023. We

will be giving more detail on our Videssa strategy in the weeks ahead as Dr.

Jorge Leon, our Chief Scientific Officer of Oncology and Infectious Diseases,

makes progress in getting the study started.

In addition, we have the

second half of an ongoing clinical trial for our LymPro Alzheimer’s blood test

at the University of Leipzig in Germany that we expect to readout in the first

half of 2022. As a reminder, this clinical study is evaluating the correlation

between LymPro scores and amyloid concentrations in the brain as measured by

SUVR, and the first half of the study showed a strong statistical significance

of the correlation with p = 0.00000216 and r = 0.85. We are very hopeful that

LymPro, a dynamic functional assay that measures immune response in the blood

that mimics ongoing pathology in the brain, will become an important tool to

qualify patients who are most likely to benefit from amyloid treatment. LymPro

measures the fundamental underlying biology of Alzheimer’s disease that we

believe can be identified at the pre-symptomatic phase given that key LymPro

markers appear to be stage-independent even at the mild cognitive impairment

(MCI) stage.

Corporate Plans for

Uplist to Nasdaq

The Company has engaged an

underwriter to support our uplisting to the Nasdaq in the first half of 2022

and we expect to file the S1 needed to complete the transaction in the near future.

The S1 is already drafted, and its filing will be a major step forward towards

that objective. We expect the clinical data from the Phase 2 clinical trial of

Tollovir to be released on January 26th, 2022 and will provide further details

around the data’s release in the weeks ahead given that we are extremely close

to completing the data lock that will trigger the analysis and data report back

to the Company from the statistical analysis group our key clinical advisor Dr.

Jules Mitchel retained to execute the analysis. We believe the data will be a

revaluation event for Todos and thereafter we will strategically plan on the

best path to achieve the Nasdaq listing that has been a key stated objective

for some time.

We are very excited about

our positioning in the marketplace at the beginning of this new year. We

believe the combination of COVID testing and Tollovid/Tollovid Daily sales that

are currently driving revenues will serve as a bridge to the transformational

revenue of Tollovir. The potential of Emergency Use Authorization (EUA) in one

or more jurisdictions in the first quarter of 2022 exists and could be a boon

to revenues should we receive it. If this happens, we plan to complete the

necessary studies to expand the number of jurisdictions in which Tollovir

receives EUAs. This would have an impact in the second half of 2022 that would

multiply sales, and position the Company financially at the same point where we

expected to be in the beginning of 2023 from launching our proprietary

diagnostics initiatives. We believe this short-term (PCR Testing / Tollovid /

Tollovid Daily), medium-term (Tollovir) and longer-term (Videssa and LymPro)

revenue strategy could layer in key revenue and provide the funding needed to

drive the next leg in revenue generation.

We are very excited about

the future for Todos, and we thank you for sharing in our vision as a

shareholder of the Company.

For more information, please

visit www.todosmedical.com. For more information

on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com.

About Todos Medical Ltd.

Founded in Rehovot, Israel with

offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers

life-saving diagnostic solutions for the early detection of a variety of

cancers. In 2021, Todos completed the acquisition of U.S.-based medical diagnostics

company Provista Diagnostics, Inc. to gain rights to its Alpharetta,

Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and

Provista’s proprietary commercial-stage Videssa® breast cancer blood test. The

Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses

(TBIA) is a proprietary cancer-screening technology using peripheral blood

analysis that deploys deep examination into cancer’s influence on the immune

system, looking for biochemical changes in blood mononuclear cells and plasma.

Todos’ two internally-developed cancer-screening tests, TMB-1 and TMB-2, have

received a CE mark in Europe. Todos is focused on the commercialization of

Videssa and will bring the TBIA tests to market thereafter.

Todos has entered into a joint

venture with NLC Pharma targeting diagnostic and testing solutions to address

the COVID-19 pandemic. The Joint-Venture is pursuing the development of

diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors

that target a fundamental reproductive mechanism of coronaviruses. The

Company’s proprietary therapeutic candidate Tollovir is currently in a Phase 2

clinical trial to treat hospitalized COVID-19 patients in Israel, and is

preparing to initiate Phase 2/3 clinical trials for both hospitalized and

non-hospitalized patients in Israel.

Todos is also developing blood

tests for the early detection of neurodegenerative disorders, such as

Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test) is a

diagnostic blood test that determines the ability of peripheral blood

lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic

stimulation that induces them to enter the cell cycle. It is believed that

certain diseases, most notably Alzheimer’s disease, are the result of

compromised cellular machinery that leads to aberrant cell cycle re-entry by

neurons, which then leads to apoptosis. LymPro is unique in the use of

peripheral blood lymphocytes as a surrogate for neuronal cell function,

suggesting a common relationship between PBLs and neurons in the brain.

Todos is also distributing

certain (COVID-19) testing materials and supplies to CLIA-certified labs in the

United States. The products cover multiple suppliers of PCR testing kits,

extraction kits, automation materials and supplies, as well as COVID-19

antibody and antigen testing kits.

For more information, please

visit https://www.todosmedical.com/.

Forward-looking Statements

Certain statements contained in

this press release may constitute forward-looking statements. For example,

forward-looking statements are used when discussing our expected clinical

development programs and clinical trials. These forward-looking statements are

based only on current expectations of management, and are subject to

significant risks and uncertainties that could cause actual results to differ

materially from those described in the forward-looking statements, including

the risks and uncertainties related to the progress, timing, cost, and results

of clinical trials and product development programs; difficulties or delays in

obtaining regulatory approval or patent protection for product candidates;

competition from other biotechnology companies; and our ability to obtain

additional funding required to conduct our research, development and

commercialization activities. In addition, the following factors, among others,

could cause actual results to differ materially from those described in the

forward-looking statements: changes in technology and market requirements;

delays or obstacles in launching our clinical trials; changes in legislation;

inability to timely develop and introduce new technologies, products and

applications; lack of validation of our technology as we progress further and

lack of acceptance of our methods by the scientific community; inability to

retain or attract key employees whose knowledge is essential to the development

of our products; unforeseen scientific difficulties that may develop with our

process; greater cost of final product than anticipated; loss of market share

and pressure on pricing resulting from competition; and laboratory results that

do not translate to equally good results in real settings, all of which could

cause the actual results or performance to differ materially from those

contemplated in such forward-looking statements. Except as otherwise required

by law, Todos Medical does not undertake any obligation to publicly release any

revisions to these forward-looking statements to reflect events or

circumstances after the date hereof or to reflect the occurrence of

unanticipated events. For a more detailed description of the risks and

uncertainties affecting Todos Medical, please refer to its reports filed from

time to time with the U.S. Securities and Exchange Commission.

Todos

Corporate and Investor Contact:

Richard Galterio

Todos Medical

732-642-7770

rich.g@todosmedical.com

References 

1.     https://assets.researchsquare.com/files/rs-1139035/v1_covered.pdf?c=1640020576

Source link

The post Todos Medical CEO Provides Letter to Shareholders first appeared on Smallcaps Daily.

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button